Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
McKinsey
Baxter
AstraZeneca
Mallinckrodt

Last Updated: December 7, 2022

CLINICAL TRIALS PROFILE FOR ULTRALENTE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ultralente

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00222521 ↗ Insulin Glargine Vs Standard Insulin Therapy Completed Moran, Antoinette, M.D. Phase 3 2003-04-01 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗ Insulin Glargine Vs Standard Insulin Therapy Completed Sanofi Phase 3 2003-04-01 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗ Insulin Glargine Vs Standard Insulin Therapy Completed University of Minnesota Phase 3 2003-04-01 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗ Insulin Glargine Vs Standard Insulin Therapy Completed University of Minnesota - Clinical and Translational Science Institute Phase 3 2003-04-01 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ultralente

Condition Name

Condition Name for Ultralente
Intervention Trials
Type 1 Diabetes 2
Cystic Fibrosis Related Diabetes 1
Diabetes Mellitus, Type 1 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ultralente
Intervention Trials
Diabetes Mellitus 4
Diabetes Mellitus, Type 1 3
Diabetes Mellitus, Type 2 2
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ultralente

Trials by Country

Trials by Country for Ultralente
Location Trials
United States 42
Canada 14
India 7
Italy 7
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ultralente
Location Trials
California 3
Nebraska 3
Kentucky 3
Texas 3
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ultralente

Clinical Trial Phase

Clinical Trial Phase for Ultralente
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ultralente
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ultralente

Sponsor Name

Sponsor Name for Ultralente
Sponsor Trials
Sanofi 2
Pfizer 2
Moran, Antoinette, M.D. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ultralente
Sponsor Trials
Other 6
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Dow
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.